KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Basic): 2009-2024

Historic EPS (Basic) for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$0.58.

  • Nektar Therapeutics' EPS (Basic) rose 29.70% to -$1.87 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.63, marking a year-over-year increase of 153.15%. This contributed to the annual value of -$0.58 for FY2024, which is 60.00% up from last year.
  • Nektar Therapeutics' EPS (Basic) amounted to -$0.58 in FY2024, which was up 60.00% from -$1.45 recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' EPS (Basic) registered a high of -$0.58 during FY2024, and its lowest value of -$2.86 during FY2021.
  • Its 3-year average for EPS (Basic) is -$1.33, with a median of -$1.45 in 2023.
  • In the last 5 years, Nektar Therapeutics' EPS (Basic) dropped by 14.86% in 2021 and then soared by 60.00% in 2024.
  • Over the past 5 years, Nektar Therapeutics' EPS (Basic) (Yearly) stood at -$2.49 in 2020, then declined by 14.86% to -$2.86 in 2021, then spiked by 31.12% to -$1.97 in 2022, then climbed by 26.40% to -$1.45 in 2023, then soared by 60.00% to -$0.58 in 2024.